Search KLH Site
Useful Links
Terms and Privacy

KLH in News

News of companies, products and development related to KLH. Full information is provided by link to third-party sites.

(in order by date)

Wednesday
Feb252015

Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma

SOURCE: Celldex, Inc.

Click to read more ...

Monday
Feb232015

Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma

SOURCE: Celldex Therapeutics, Inc.

Click to read more ...

Tuesday
Dec092014

Parkinson’s Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS AG

SOURCE: AFFiRis

Click to read more ...

Tuesday
Nov112014

Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

Thursday
Oct232014

Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

Monday
Apr072014

Neovacs completes enrollment for phase IIb of TNF-Kinoid

Source: Neovacs

Click to read more ...

Monday
Mar032014

Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference

SOURCE: Stellar Biotechnologies, Inc.

Click to read more ...

Monday
Jan132014

European Medicines Agency Accepts Marketing Authorization Application for Biovest’s Cancer Vaccine for Treatment of Non-Hodgkin’s Follicular Lymphoma

SOURCE: Biovest, Inc.

Click to read more ...

Monday
Dec092013

Neovacs: First patients enrolled in Phase IIb study of TNF-Kinoid for Rheumatoid Arthritis

SOURCE: Neovacs

Click to read more ...

Monday
Nov112013

Celldex Therapeutics Announces Publication of Preliminary Data from the Phase 2 ReACT Study to be Presented at the 18th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)

SOURCE: Celldex Therapeutics, Inc.

Click to read more ...